Vaccine · Immune activation · developed by Vaxcyte
VAX-A1 is a vaccine administered by intramuscular injection into the deltoid muscle at low, mid and high doses. It is studied for the prevention of group A streptococcal infection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07616934 | Phase 1 | Group A Streptococcal Infection | Recruiting | PCVX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Group A Streptococcal Infection
Updated Oct 25, 2026. Something wrong or missing? Report it on the PCVX page.
See PCVX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PCVX catalysts and pipeline →